FOLFOXIRI + bevacizumab versus FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable colorectal liver metastases (CRLM) and right-sided and/or <i>RAS</i>/<i>BRAFV600E-</i>mutated primary tumor: Phase III CAIRO5 study of the Dutch Colorectal Cancer Group.
Cornelis J.A. Punt(Utrecht University), Rutger‐Jan Swijnenburg(Amsterdam University Medical Centers), Marinde J. G. Bond(Utrecht University), Cornelis Verhoef(Erasmus MC Cancer Institute), Helgi H. Helgason(Medisch Centrum Haaglanden), Emile D. Kerver(OLVG), Mathijs P. Hendriks(Northwest Hospital), Mike S.L. Liem(Medisch Spectrum Twente), Jan Willem de Groot(Isala), Geert Kazemier(European Organisation for Research and Treatment of Cancer), Joost M. Klaase(University Medical Center Groningen), Karen Bolhuis(The Netherlands Cancer Institute), Aysun Komurcu(Netherlands Comprehensive Cancer Organisation), Arjen M. Rijken(Amphia Ziekenhuis), Johannes H.W. de Wilt(Radboud University Nijmegen), Martinus J. van Amerongen(Sint Maartenskliniek), Marc Engelbrecht(University of Amsterdam), Marta López‐Yurda(The Netherlands Cancer Institute), O. J. L. Loosveld(Amphia Ziekenhuis), Koert P. de Jong(University of Padua)
Cited by 14
Related Papers
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2010|1k
From tumour heterogeneity to advances in precision treatment of colorectal cancer
|Nature Reviews Clinical Oncology|2016|692